Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Motesanib
CHF 78.00
In stock
SYN-1055-M0011 mgCHF 78.00
SYN-1055-M0055 mgCHF 132.00
SYN-1055-M01010 mgCHF 209.00
SYN-1055-M05050 mgCHF 658.00
SYN-1055-M100100 mgCHF 1'185.00
| Product Details | |
|---|---|
| Synonyms | AMG706 |
| Product Type | Chemical |
| Properties | |
| Formula | C22H23N5O |
| MW | 373.5 |
| CAS | 453562-69-1 |
| Purity Chemicals | ≥95% |
| Appearance | Solid. |
| Solubility | Soluble in DMSO or ethanol. |
| Declaration | Manufactured by SynKinase. |
| Other Product Data |
Target: PDGFR | Kinase Group: RTK | Substrate: Tyrosine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
| InChi Key | RAHBGWKEPAQNFF-UHFFFAOYSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Motesanib (AMG 706) is a multi-targeted anti-cancer agent with an inhibitory action on human vascular endothelial growth factor receptors 1, 2 and 3 (VEGFR1-3) with IC(50) values of 2nM, 3nM and 6nM. It also inhibits platelet-derived growth factor receptor (PDGFR) and cellular stem-cell factor receptor (c-KIT).
Product References
- AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts: A. Polverino, et al.; Cancer Res. 66, 8715 (2006)
Related Products
